KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xenon Pharmaceuticals (XENE) Cash & Equivalents (2016 - 2025)

Historic Cash & Equivalents for Xenon Pharmaceuticals (XENE) over the last 13 years, with Q3 2025 value amounting to $555.3 million.

  • Xenon Pharmaceuticals' Cash & Equivalents rose 53370.2% to $555.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $555.3 million, marking a year-over-year increase of 53370.2%. This contributed to the annual value of $754.4 million for FY2024, which is 40752.54% up from last year.
  • Xenon Pharmaceuticals' Cash & Equivalents amounted to $555.3 million in Q3 2025, which was up 53370.2% from $624.8 million recorded in Q2 2025.
  • Xenon Pharmaceuticals' 5-year Cash & Equivalents high stood at $754.4 million for Q4 2024, and its period low was $57.2 million during Q4 2022.
  • Moreover, its 5-year median value for Cash & Equivalents was $103.5 million (2022), whereas its average is $199.9 million.
  • In the last 5 years, Xenon Pharmaceuticals' Cash & Equivalents plummeted by 8255.29% in 2023 and then surged by 53370.2% in 2025.
  • Xenon Pharmaceuticals' Cash & Equivalents (Quarter) stood at $175.7 million in 2021, then tumbled by 67.42% to $57.2 million in 2022, then soared by 159.67% to $148.6 million in 2023, then skyrocketed by 407.53% to $754.4 million in 2024, then dropped by 26.4% to $555.3 million in 2025.
  • Its Cash & Equivalents was $555.3 million in Q3 2025, compared to $624.8 million in Q2 2025 and $116.7 million in Q1 2025.